SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
6 Hope St Ermington NSW 2115
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)we understand Reva Medical Inc's shares were cancelled and had zero value after a Chapter 11 restructuring in the US. This occured in 2020 and as a consequence shareholder losses are thus crystallised for Capital Gains Tax purposes - as always shareholders should seek independent professional advice on tax matters | 20/02/2025 |
Strike Off Action in Progress | 08/02/2024 |
delisted from the close of trading on Wednesday, 28 August 2019 pursuant to Listing rule 17.15. | 28/08/2019 |
we understand this company failed to pay its annual listing fee on due date and ASX has accordingly removed it from the official list | 28/08/2019 |
The company has not paid their annual listing fees in respect of the year ending 30 June 2020 but the securities are already suspended from official quotation. | 22/08/2019 |
The company has received an additional $1.2 million in funding as part of the April 2019 senior secured credit facility to continue to support operations on an interim basis. The funding is a multi-draw term loan and has been made available by existing lenders to the company. | 05/08/2019 |
The company has executed a credit and guaranty agreement for a $3.8 million, Senior Secured Credit Facility to fund operations on an interim basis. The funding is a Multi-Draw Term Loan and has been made available by existing lenders to the Company. In connection with the Agreement, the Company will pay approximately $0.8 million in fees, resulting in net funding of $3 million. Additionally, REVA announced that the Company entered into an amendment to that certain Exclusive License Agreement Number 2, dated 1 July 2010, by and between Rutgers, The State University of New Jersey and the Company related to the composition and coating of the Company's bioresorbable scaffolds and its other biomaterial products. | 08/04/2019 |
The company has secured a letter of commitment for up to $3 million of debt financing to fund operations on an interim basis. The funding will be made available by existing lenders to the Company. The funding is subject to the negotiation and execution of definitive agreements and a further announcement will be made once those agreements are executed. The funding is to address the Company's immediate financial needs on an interim basis, but the Company remains in discussions about a broader restructure to address the Company's outstanding indebtedness and capital structure moving forward. | 25/03/2019 |
The company is extending the voluntary suspension of trading until it can finalise its plans and provide the market with an accurate update on its future plans. The company expects to be able to make an announcement regarding its finalised plans by 21 March 2019. | 13/03/2019 |
S&P DJI Announces March 2019 Quarterly Rebalance. | 08/03/2019 |
The voluntary suspension is expected to continue until plans are finalised and an announcement is made to the ASX. The company is expecting that it will be able to make an announcement by 13 March 2019. | 06/03/2019 |
The company requests the voluntary suspension of its securities continue until it can finalise its plans and provide the market with an accurate update on its future plans. The suspension is expected to continue until the financial debt and or equity raising details are finalised and an announcement is made to the ASX in this regard. It is expected to be able to do so by 6 March 2019. | 25/02/2019 |
The company issues a response to ASX Appendix 4C Query Letter. | 22/02/2019 |
The securities of Reva Medical, Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of RVA, pending the release of an announcement regarding capital raising activities. | 20/02/2019 |
listed entity carried for record purposes only | 23/12/2010 |
A fabulous product that could save many lives. Bad management, I suppose. Someone should buy up the product, if not the company. | 19/05/2021 11:34:18 |
I would like to know what is the situation with this company. I have shares and have had no correspondence in relation to where they are and if they are worth anything. Very poor communication. | 12/01/2020 11:53:49 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 29/06/2018 | Regina Groves | 98,157 | $0.207 | $20,309.00 |
| 29/06/2018 | Robert Stockman | 327,191 | $0.207 | $67,696.00 |
| 29/06/2018 | Ray Larkin | 196,315 | $0.207 | $40,618.00 |
| 29/06/2018 | Stephen Oesterle | 163,596 | $0.207 | $33,848.00 |
| 29/06/2018 | Robert Thomas | 163,596 | $0.207 | $33,848.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Ray Larkin | Chairman | 14/07/2017 |
| Leigh Elkolli | CFO, Company Secretary | 04/01/2019 |
| Ross Breckenridge | Non Exec Director | 29/01/2015 |
| Robert Stockman | Non Exec Director | 01/12/1999 |
| Robert Thomas | Director | 28/07/2010 |
| Brian Dovey | Director | 12/06/2001 |
| Stephen Oesterle | Director | 05/02/2018 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
